Abstract
AbstractBreast cancer is a highly prevalent malignancy that affects a significant number of women around the world. This is the leading cause of cancer‐related mortality among women. Various therapeutic approaches have been introduced to fight against it, including surgery, radiation therapy, hormone therapy, chemotherapy, and biological therapies. However, attention to research and the development of innovative therapeutic interventions to reduce toxicity and increase treatment efficacy is always ongoing. As a novel method of treatment, gene therapy for modifying inappropriate genes and treating various types of cancer has gained attention. The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology is a significant advancement in genetic editing that has gained widespread use in human cancer research and gene therapy. It is highly valued for its precision, specificity, cost‐effectiveness, and time‐saving properties with minimal risk. Our review focuses on CRISPR/Cas9's role as a targeted therapeutic approach for enhancing immunotherapy and overcoming drug resistance in breast cancer.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
